ATE291437T1 - Verwendung von botulinustoxin zur gewinnung eines produkts für die verwendung bei gelenkerkrankungen, insbesondere hüftgelenkarthrose, epicondylitis und rotatorkappenerkrankungen - Google Patents

Verwendung von botulinustoxin zur gewinnung eines produkts für die verwendung bei gelenkerkrankungen, insbesondere hüftgelenkarthrose, epicondylitis und rotatorkappenerkrankungen

Info

Publication number
ATE291437T1
ATE291437T1 AT02727002T AT02727002T ATE291437T1 AT E291437 T1 ATE291437 T1 AT E291437T1 AT 02727002 T AT02727002 T AT 02727002T AT 02727002 T AT02727002 T AT 02727002T AT E291437 T1 ATE291437 T1 AT E291437T1
Authority
AT
Austria
Prior art keywords
epicondylitis
disease
product
joint diseases
botulinus toxin
Prior art date
Application number
AT02727002T
Other languages
English (en)
Inventor
Corrado Marchini
Fabiano Pinat
Fabio Pinat
Francesca Zecchini
Original Assignee
Univ Degli Studi Udine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11460457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE291437(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Degli Studi Udine filed Critical Univ Degli Studi Udine
Application granted granted Critical
Publication of ATE291437T1 publication Critical patent/ATE291437T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02727002T 2001-01-05 2002-01-04 Verwendung von botulinustoxin zur gewinnung eines produkts für die verwendung bei gelenkerkrankungen, insbesondere hüftgelenkarthrose, epicondylitis und rotatorkappenerkrankungen ATE291437T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001UD000002A ITUD20010002A1 (it) 2001-01-05 2001-01-05 Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
PCT/IB2002/000003 WO2002053175A2 (en) 2001-01-05 2002-01-04 Use of botulinum toxin for treatment of articular pathologies

Publications (1)

Publication Number Publication Date
ATE291437T1 true ATE291437T1 (de) 2005-04-15

Family

ID=11460457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727002T ATE291437T1 (de) 2001-01-05 2002-01-04 Verwendung von botulinustoxin zur gewinnung eines produkts für die verwendung bei gelenkerkrankungen, insbesondere hüftgelenkarthrose, epicondylitis und rotatorkappenerkrankungen

Country Status (15)

Country Link
US (2) US7208166B2 (de)
EP (1) EP1357937B1 (de)
JP (1) JP2004517114A (de)
CN (1) CN1318089C (de)
AT (1) ATE291437T1 (de)
AU (1) AU2002222432B8 (de)
CA (1) CA2433765C (de)
CY (1) CY1105490T1 (de)
DE (1) DE60203370T2 (de)
DK (1) DK1357937T3 (de)
ES (1) ES2242858T3 (de)
IT (1) ITUD20010002A1 (de)
PT (1) PT1357937E (de)
RU (1) RU2283664C2 (de)
WO (1) WO2002053175A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE60326887D1 (de) * 2002-12-20 2009-05-07 Botulinum Toxin Res Ass Inc Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
AU2005271582B2 (en) * 2004-08-03 2010-09-16 Igt Gaming method and device involving progressive wagers
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
RU2496150C1 (ru) * 2012-04-16 2013-10-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный университет им. Ф.М. Достоевского" Способ моделирования костной кристаллизации при коксартрозе in vitro
US9492513B2 (en) * 2013-04-25 2016-11-15 Allergan, Inc. Methods for treatment of hip and groin pain associated with femoroacetabular impingement (FAI)
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN105567739B (zh) * 2016-02-04 2019-07-12 郑州可尔利尔生物科技有限公司 病毒载体颗粒及其构建方法和应用
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
RU2112446C1 (ru) * 1992-11-05 1998-06-10 Дагестанский государственный медицинский институт Способ лечения болезни пертеса
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ES2159624T3 (es) 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries

Also Published As

Publication number Publication date
ES2242858T3 (es) 2005-11-16
CA2433765A1 (en) 2002-07-11
CN1491115A (zh) 2004-04-21
DK1357937T3 (da) 2005-08-01
WO2002053175A2 (en) 2002-07-11
CN1318089C (zh) 2007-05-30
RU2003124186A (ru) 2005-01-10
US20040071735A1 (en) 2004-04-15
WO2002053175A3 (en) 2002-09-12
CY1105490T1 (el) 2010-04-28
PT1357937E (pt) 2005-08-31
US20070020294A1 (en) 2007-01-25
US7208166B2 (en) 2007-04-24
AU2002222432B8 (en) 2006-04-27
DE60203370D1 (de) 2005-04-28
AU2002222432B2 (en) 2006-04-13
EP1357937B1 (de) 2005-03-23
ITUD20010002A1 (it) 2002-07-05
EP1357937A2 (de) 2003-11-05
RU2283664C2 (ru) 2006-09-20
JP2004517114A (ja) 2004-06-10
CA2433765C (en) 2008-10-28
DE60203370T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE291437T1 (de) Verwendung von botulinustoxin zur gewinnung eines produkts für die verwendung bei gelenkerkrankungen, insbesondere hüftgelenkarthrose, epicondylitis und rotatorkappenerkrankungen
PT1303632E (pt) Oligossacarideos de galactomanano e processo para a sua preparacao bem como sua utilizacao
FR2850646B1 (fr) Corps photostructurable, procede pour le traitement d'un verre et/ou d'une vitroceramique, production de divers produits qui en sont derives, leur utilisation et objet utilisant ledit corps
IL132293A0 (en) Use of lactoferin in the treatment of allergen induced disorders
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
PE110499A1 (es) Proceso para aislar una composicion proteica de una fuente muscular
BR0116356A (pt) Lente de contato com modelo de ìris opaco
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
AU305825S (en) Bottle
PL366800A1 (en) Tablet comprising cetirizine and pseudoephedrine
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
EP1997510A8 (de) Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfall
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
MY129643A (en) Tablet comprising cetirizine and pseudoephedrine
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
BR0307341A (pt) Delta1-pirrolinas
WO1998031712A3 (en) Chitosan-conjugates with acidic chelate-complex forming agents
DE59808193D1 (de) Neue vitamin d-derivate mit cyclopropylringen in den seitenketten, verfahren und zwischenprodukte zu ihrer herstellung sowie ihre verwendung zur herstellung von arzneimitteln
BR0106880A (pt) Tubulação metálica revestida com um polìmero termoplástico para o transporte de produtos de petróleo, e, processo para revestir uma tubulação metálica com uma camisa termoplástica
DE10084841T1 (de) Brikett, geeignet zur Verflüssigung von Hüttenschlacke, und die Brikett-Herstellungsmethode
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
AU303903S (en) A bottle
NZ514691A (en) Method to type prion proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1357937

Country of ref document: EP

EEIH Change in the person of patent owner
RZN Patent revoked